Ginna Laport, VP and Global Head of Lymphoma at Genentech discusses types of blood cancers, the historic treatment challenges, and new research and treatment options that are changing the way people fight cancer. Recent studies show new innovative treatments that fight cancer without chemotherapy are effective and safe and could help a wide range of patients in need. She also talks about the impact COVID-19 has had on patient regimens.
Ginna is the current VP and Global Head of Lymphoma as part of the chronic lymphocytic leukemia franchise. Prior to Genentech, she was a CMO at Tempest Therapeutics and part of the clinical development team at Corvus Pharmaceuticals. During Ginna’s tenure in academia, she was faculty in the Stanford University School of Medicine, most recently as a professor in the Division of Blood and Marrow Transplantation (BMT). Her research focused on adoptive immunotherapies for malignant diseases and she served as director of clinical research in the BMT Division and as an associate director of the Stanford Cancer Institute.